Quick reference manual for silicon integrated circuits technology / за авторством Beadle, W. E., Tsai, J. C. C., Plummer, R. D.

Clinical development of new drug-radiotherapy combinations. за авторством Sharma, R, Plummer, R, Stock, J, Greenhalgh, T, Hawkins, M, NCRI CTRad Academia-Pharma Joint Working Group

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours за авторством Wilson, R, Jeffry Evans, T, Middleton, M, Molife, L, Spicer, J, Dieras, V, Roxburgh, P, Giordano, H, Jaw-Tsai, S, Goble, S, Plummer, R

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation... за авторством Plummer, R, Lorigan, P, Steven, N, Scott, L, Middleton, M, Wilson, R, Mulligan, E, Curtin, N, Wang, D, Dewji, R, Abbattista, A, Gallo, J, Calvert, H

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. за авторством Harrington, K, Billingham, L, Brunner, T, Burnet, N, Chan, C, Hoskin, P, Mackay, R, Maughan, T, Macdougall, J, Mckenna, W, Nutting, C, Oliver, A, Plummer, R, Stratford, I, Illidge, T

Radiotherapy research priorities for the UK. за авторством Maughan, T, Illidge, T, Hoskin, P, Mckenna, W, Brunner, T, Stratford, I, Harrington, K, Plummer, R, Billingham, L, Nutting, C, Burnet, N, Mackay, R, Oliver, A, Young, C, Chan, C

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. за авторством Gupta, A, Love, S, Schuh, A, Shanyinde, M, Larkin, J, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Collins, L, Wise, A, Asher, R, Lisle, R, Middleton, MR

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers за авторством Harrington, K, Billingham, L, Brunner, T, Burnet, N, Chan, C, Hoskin, P, MacKay, R, Maughan, T, MacDougall, J, Mckenna, W, Nutting, C, Oliver, A, Plummer, R, Stratford, I, Illidge, T

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules... за авторством Boss, D, Schwartz, G, Middleton, MR, Amakye, D, Swaisland, H, Midgley, R, Ranson, M, Danson, S, Calvert, H, Plummer, R, Morris, C, Carvajal, R, Chirieac, L, Schellens, J, Shapiro, G

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma за авторством Gupta, A, Love, S, Schuh, A, Collins, L, Thomason, A, Asher, R, Lisle, R, Churchman, M, Shanyinde, M, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Larkin, J, Middleton, MR

An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib за авторством Mateo, J, Moreno, V, Gupta, A, Kaye, S, Dean, E, Middleton, M, Friedlander, M, Gourley, C, Plummer, R, Rustin, G, Sessa, C, Leunen, K, Ledermann, J, Swaisland, H, Fielding, A, Bannister, W, Nicum, S, Molife, L

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. за авторством Plummer, R, Jones, C, Middleton, M, Wilson, R, Evans, J, Olsen, A, Curtin, N, Boddy, A, McHugh, P, Newell, D, Harris, A, Johnson, P, Steinfeldt, H, Dewji, R, Wang, D, Robson, L, Calvert, H

A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases за авторством Plummer R, Greystoke A, Naylor G, Sarker D, Anam ANMK, Prenen H, Teuwen LA, Van Cutsem E, Dekervel J, Haugk B, Ness T, Bhoi S, Jensen M, Morris T, Baumann P, Sjögren N, Tunblad K, Wallberg H, Öberg F, Evans TRJ

Отримати повний текст

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors за авторством Soria, J, Gan, H, Blagden, S, Plummer, R, Arkenau, H, Ranson, M, Evans, T, Zalcman, G, Bahleda, R, Hollebecque, A, Lemech, C, Dean, E, Brown, J, Gibson, D, Peddareddigari, V, Murray, S, Nebot, N, Mazumdar, J, Swartz, L, Auger, K, Fleming, R, Singh, R, Millward, M

Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. за авторством Leach, M, Morgan, B, Tofts, P, Buckley, D, Huang, W, Horsfield, M, Chenevert, T, Collins, D, Jackson, A, Lomas, D, Whitcher, B, Clarke, L, Plummer, R, Judson, I, Jones, R, Alonzi, R, Brunner, T, Koh, D, Murphy, P, Waterton, J, Parker, G, Graves, M, Scheenen, T, Redpath, T, Orton, M

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients за авторством S Ahmad, S, Qian, W, Ellis, S, Mason, E, Khattak, M, Gupta, A, Shaw, H, Quinton, A, Kovarikova, J, Thillai, K, Rao, A, Board, R, Nobes, J, Dalgleish, A, Grumett, S, Maraveyas, A, Danson, S, Talbot, T, Harries, M, Marples, M, Plummer, R, Kumar, S, Nathan, P, Middleton, M, Larkin, J, Lorigan, P, Wheater, M, Ottensmeier, C, Corrie, P